1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Combating Antibiotic-Resistant Bacteria Interdisciplinary Research Units (CARBIRUs) (P01, Clinical Trial Not Allowed) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
This funding opportunity supports multidisciplinary, collaborative research programs focused on discovery to early development research to inform new approaches to prevent, diagnose, and treat antibiotic-resistant bacterial infections, including Clostridioides difficile.
Research areas include understanding mechanisms of resistance, discovering novel drug targets, characterizing new antibiotics and non-antibiotic products (like bacteriophage and live microbiome-based products), and developing rapid diagnostics.
Get alerted about grants like this
Get emailed when new opportunities from “National Institute of Allergy and Infectious Diseases (NIAID)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: This program supports interdisciplinary research units. While specific eligibility for P01 grants can be broad, they are generally open to institutions, organizations, and businesses that can conduct complex research programs. Clostridioides difficile is an explicitly mentioned bacterial pathogen of interest. Confirm the full requirements in the official notice before applying.
The published deadline was March 26, 2025, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Combating Antibiotic-Resistant Bacteria Interdisciplinary Research Units (CARBIRUs) (P01, Clinical Trial Not Allowed) is funded by National Institute of Allergy and Infectious Diseases (NIAID). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Research Project Grant (Parent R01 Clinical Trial Not Allowed) is a flagship NIH grant administered by the National Institute of Allergy and Infectious Diseases that funds investigator-initiated biomedical and behavioral research projects not involving clinical trials. The R01 supports hypothesis-driven research across a wide range of health topics including infectious diseases, immune disorders, and allergy-related conditions. Eligible applicants include higher education institutions such as public and private universities. Award amounts range from $250,000 to $2,500,000 with a deadline of June 5, 2026.
Tuberculosis Research Advancement Centers (TRACs) (P30 Clinical Trial Not Allowed) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) - NIH. The TRACs program aims to develop the next generation of TB researchers and catalyze multidisciplinary and innovative TB science by providing expertise and resources to facilitate basic and clinical TB research.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.